PMID: 18414063Apr 17, 2008Paper

Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition

Cell Cycle
Marianne S PoruchynskyTito Fojo

Abstract

Bortezomib (Velcade((R))), a proteasome inhibitor, is approved by the FDA for the treatment of multiple myeloma (MM). While effective, its use has been hampered by peripheral neurotoxicity of unexplained etiology. Since proteasome inhibitors alter protein degradation, we speculated that proteins regulating microtubule (MT) stability may be affected after treatment and examined MT polymerization in cells by comparing the distribution of tubulin between polymerized (P) and soluble (S) fractions. We observed increased MT polymerization following treatment of SY5Y and KCNR [neuroblastoma], HCN2, and 8226 [MM] cells, using five proteasome inhibitors; the baseline proportion of total alpha-tubulin in 'P' fractions ranged from approximately 41-68%, and increased to approximately 55-99% after treatment. Increased acetylated alpha-tubulin, a post-translational marker of stabilized MTs, was observed in the neural cell lines HCN1A and HCN2 and this was sustained up to 144 hours after the proteasome inhibitor was removed. Cell cycle analysis of three cell lines after treatment, showed approximately 50-75% increases in the G(2)M phase. Immunofluorescent localization studies of proteasome inhibitor treated cells did not reveal microtubule bu...Continue Reading

Citations

Sep 3, 2013·Current Pain and Headache Reports·Jérémy FerrierDavid Balayssac
Dec 31, 2010·Current Treatment Options in Neurology·Guido CavalettiEmanuela Susani
Oct 12, 2010·The Lancet Oncology·Michel DelforgePieter Sonneveld
Oct 5, 2010·Nature Reviews. Drug Discovery·Charles Dumontet, Mary Ann Jordan
Feb 15, 2014·Neurotoxicology·Albert AléEsther Udina
Jul 30, 2014·Archives of Toxicology·Andreas A ArgyriouHaralabos P Kalofonos
Sep 5, 2008·Current Opinion in Neurology·Anthony BehinJean-Marc Leger
May 26, 2010·Leukemia & Lymphoma·Guido Cavaletti, Andrzej J Jakubowiak
Feb 10, 2010·Expert Opinion on Investigational Drugs·Si-Meng ChenJian Ding
Jan 22, 2015·Proceedings of the National Academy of Sciences of the United States of America·Marianne S PoruchynskyAntonio Tito Fojo
Nov 18, 2014·Hematological Oncology·Marta MorawskaMarek Hus
Feb 6, 2010·Cancer Letters·William Ka Kei WuJoseph Jao Yiu Sung
Nov 17, 2009·Advanced Drug Delivery Reviews·Ho Lun WongReina Bendayan
Oct 19, 2011·Journal of the Peripheral Nervous System : JPNS·Jordi BrunaEsther Udina
Mar 5, 2014·CA: a Cancer Journal for Clinicians·Susanna B ParkMatthew C Kiernan
May 16, 2014·CPT: Pharmacometrics & Systems Pharmacology·J HurJ P F Bai
Dec 3, 2014·Neuroscience Letters·V A CarozziA Chiorazzi
Jan 16, 2015·Neurotoxicity Research·Albert AléEsther Udina
Jan 18, 2011·Hematology·Pieter Sonneveld, Joost L M Jongen
Dec 13, 2016·Free Radical Biology & Medicine·Gulce Sari KaplanBetul Karademir
Oct 4, 2017·British Journal of Pharmacology·Natalie A Duggett, Sarah J L Flatters
Jul 14, 2016·F1000Research·James Addington, Miriam Freimer
Sep 11, 2009·Leukemia·J J Shah, R Z Orlowski
Dec 1, 2015·Cellular & Molecular Biology Letters·Flora De ContoAdriana Calderaro
Sep 16, 2017·Frontiers in Neuroscience·Yusuke FukudaRosalind A Segal
Jul 27, 2015·Toxics·Cristina Meregalli
Jun 5, 2015·Toxics·Annalisa CantaValentina Alda Carozzi
Jun 15, 2019·International Journal of Molecular Sciences·Laura BrandoliniAnnamaria Cimini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Cycle Control & Proteolysis

Key regulators of cell cycle, including cyclins, cyclin dependent kinase inhibitors, DNA replication factors, are controlled by proteolysis. Discover the latest research on cell cycle control and proteolysis.